Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 6/2016

Open Access 01-12-2016 | Position Papers and Guidelines

Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement

Published in: Journal of Nephrology | Issue 6/2016

Login to get access

Abstract

Background

Recently published guidelines on the medical management of renal stone disease did not address relevant topics in the field of idiopathic calcium nephrolithiasis, which are important also for clinical research.

Design

A steering committee identified 27 questions, which were proposed to a faculty of 44 experts in nephrolithiasis and allied fields. A systematic review of the literature was conducted and 5216 potentially relevant articles were selected; from these, 407 articles were deemed to provide useful scientific information. The Faculty, divided into working groups, analysed the relevant literature. Preliminary statements developed by each group were exhaustively discussed in plenary sessions and approved.

Results

Statements were developed to inform clinicians on the identification of secondary forms of calcium nephrolithiasis and systemic complications; on the definition of idiopathic calcium nephrolithiasis; on the use of urinary tests of crystallization and of surgical observations during stone treatment in the management of these patients; on the identification of patients warranting preventive measures; on the role of fluid and nutritional measures and of drugs to prevent recurrent episodes of stones; and finally, on the cooperation between the urologist and nephrologist in the renal stone patients.

Conclusions

This document has addressed idiopathic calcium nephrolithiasis from the perspective of a disease that can associate with systemic disorders, emphasizing the interplay needed between urologists and nephrologists. It is complementary to the American Urological Association and European Association of Urology guidelines. Future areas for research are identified.
Literature
1.
Pearle MS, Goldfarb DS, Assimos DG et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192(2):316–324PubMedCrossRef
2.
Fink HA, Wilt TJ, Eidman KE et al (2013) Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158(7):535–543PubMedCrossRef
3.
Skolarikos A, Straub M, Knoll T et al (2015) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 67(4):750–763PubMedCrossRef
4.
5.
Shoag J, Halpern J, Goldfarb DS, Eisner BH (2014) Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J Urol 192(5):1440–1445PubMedCrossRef
6.
Saucier NA, Sinha MK, Liang KV et al (2010) Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis 55(1):61–68PubMedCrossRef
7.
El-Zoghby ZM, Lieske JC, Foley RN et al (2012) Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol CJASN 7(9):1409–1415PubMedCrossRef
8.
Gillen DL, Worcester EM, Coe FL (2005) Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 67(2):685–690PubMedCrossRef
9.
Worcester EM, Parks JH, Evan AP, Coe FL (2006) Renal function in patients with nephrolithiasis. J Urol 176(2):600–603 (discussion 603)
10.
Prot-Bertoye C, Lebbah S, Daudon M et al (2015) CKD and Its risk factors among patients with cystinuria. Clin J Am Soc Nephrol CJASN 10(5):842–851PubMedCrossRef
11.
Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG (2015) Kidney stones are common after bariatric surgery. Kidney Int 87(4):839–845PubMedCrossRef
12.
Bucuras V, Gopalakrishnam G, Wolf JS et al (2012) The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: nephrolithotomy in 189 patients with solitary kidneys. J Endourol 26(4):336–341PubMedCrossRef
13.
Tasca A, Dalle Carbonare L, Nigro F, Giannini S (2009) Bone disease in patients with primary hypercalciuria and calcium nephrolithiasis. Urology 74(1):22–27PubMedCrossRef
14.
Melton LJ, Crowson CS, Khosla S, Wilson DM, O’Fallon WM (1998) Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 53(2):459–464PubMedCrossRef
15.
Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD (2003) Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol 169(2):465–469PubMedCrossRef
16.
Sakhaee K, Maalouf NM, Kumar R, Pasch A, Moe OW (2011) Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 79(4):393–403PubMedCrossRef
17.
Bushinsky DA, Willett T, Asplin JR, Culbertson C, Che SPY, Grynpas M (2011) Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats. J Bone Miner Res Off J Am Soc Bone Miner Res 26(8):1904–1912CrossRef
18.
Krieger NS, Asplin JR, Frick KK et al (2015) Effect of potassium citrate on calcium phosphate stones in a model of hypercalciuria. J Am Soc Nephrol JASN 26(12):3001–3008PubMedCrossRef
19.
Jehle S, Hulter HN, Krapf R (2013) Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 98(1):207–217PubMedCrossRef
20.
Borghi L, Schianchi T, Meschi T et al (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346(2):77–84PubMedCrossRef
21.
Miller NL, Williams JC, Evan AP et al (2010) In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall’s plaque. BJU Int 105(2):242–245PubMedCrossRef
22.
Goldfarb DS, Arowojolu O (2013) Metabolic evaluation of first-time and recurrent stone formers. Urol Clin North Am 40(1):13–20PubMedCrossRef
23.
Fabris A, Ferraro PM, Comellato G et al (2015) The relationship between calcium kidney stones, arterial stiffness and bone density: unraveling the stone-bone-vessel liaison. J Nephrol 28(5):549–555PubMedCrossRef
24.
Hess B, Hasler-Strub U, Ackermann D, Jaeger P (1997) Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 12(7):1362–1368
25.
Letavernier E, Traxer O, Daudon M et al (2011) Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria. Clin J Am Soc Nephrol CJASN 6(5):1149–1154PubMedCrossRef
26.
Linnes MP, Krambeck AE, Cornell L et al (2013) Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int 84(4):818–825PubMedPubMedCentralCrossRef
27.
Wang X, Krambeck AE, Williams JC et al (2014) Distinguishing characteristics of idiopathic calcium oxalate kidney stone formers with low amounts of Randall’s plaque. Clin J Am Soc Nephrol CJASN 9(10):1757–1763PubMedCrossRef
28.
Dhayat NA, Schaller A, Albano G, et al (2015) The Vacuolar H+-ATPase B1 Subunit Polymorphism p.E161 K Associates with Impaired Urinary Acidification in Recurrent Stone Formers. J Am Soc Nephrol JASN
29.
Esposito T, Rendina D, Aloia A et al (2012) The melatonin receptor 1A (MTNR1A) gene is associated with recurrent and idiopathic calcium nephrolithiasis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 27(1):210–218
30.
Ferraro PM, D’Addessi A, Gambaro G (2013) When to suspect a genetic disorder in a patient with renal stones, and why. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 28(4):811–820
31.
32.
33.
Evan AP, Lingeman JE, Worcester EM, et al (2014) Contrasting histopathology and crystal deposits in kidneys of idiopathic stone formers who produce hydroxy apatite, brushite, or calcium oxalate stones. Anat Rec Hoboken NJ 2007 297(4):731–48
34.
Pak CYC, Poindexter JR, Adams-Huet B, Pearle MS (2003) Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 115(1):26–32PubMedCrossRef
35.
Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE (2004) Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int 66(2):777–785PubMedCrossRef
36.
Evan AP, Coe FL, Connors BA, Handa RK, Lingeman JE, Worcester EM (2015) Mechanism by which shock wave lithotripsy can promote formation of human calcium phosphate stones. Am J Physiol Renal Physiol 308(8):F938–F949PubMedPubMedCentralCrossRef
37.
Zhang J, Fuster DG, Cameron MA et al (2014) Incomplete distal renal tubular acidosis from a heterozygous mutation of the V-ATPase B1 subunit. Am J Physiol Renal Physiol 307(9):F1063–F1071PubMedPubMedCentralCrossRef
38.
Osther PJ, Hansen AB, Röhl HF (1988) Renal acidification defects in patients with their first renal stone episode. Scand J Urol Nephrol Suppl 110:275–278PubMed
39.
Williams G, Chisholm GD (1975) Stone screening and follow-up are necessary? Br J Urol 47(7):745–750PubMedCrossRef
40.
Pak CYC, Poindexter JR, Peterson RD, Heller HJ (2004) Biochemical and physicochemical presentations of patients with brushite stones. J Urol 171(3):1046–1049PubMedCrossRef
41.
Preminger GM, Sakhaee K, Skurla C, Pak CY (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134(1):20–23PubMed
42.
Fabris A, Lupo A, Bernich P et al (2010) Long-term treatment with potassium citrate and renal stones in medullary sponge kidney. Clin J Am Soc Nephrol CJASN 5(9):1663–1668PubMedCrossRef
43.
44.
Coe FL, Raisen L (1973) Allopurinol treatment of uric-acid disorders in calcium-stone formers. Lancet Lond Engl 1(7795):129–131CrossRef
45.
46.
Curhan GC, Taylor EN (2008) 24-h uric acid excretion and the risk of kidney stones. Kidney Int 73(4):489–496PubMedCrossRef
47.
48.
Coe FL, Kavalach AG (1974) Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 291(25):1344–1350PubMedCrossRef
49.
Pak CY, Barilla DE, Holt K, Brinkley L, Tolentino R, Zerwekh JE (1978) Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. Am J Med 65(4):593–599PubMedCrossRef
50.
Pak CY, Waters O, Arnold L, Holt K, Cox C, Barilla D (1977) Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest 59(3):426–431PubMedPubMedCentralCrossRef
51.
Grover PK, Marshall VR, Ryall RL (2003) Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol 10(3):271–278PubMedCrossRef
52.
Grover PK, Ryall RL (2002) The effect of preincubation of seed crystals of uric acid and monosodium urate with undiluted human urine to induce precipitation of calcium oxalate in vitro : implications for urinary stone formation. Mol Med Camb Mass 8(9):525–535PubMedPubMedCentral
53.
Coe FL, Lawton RL, Goldstein RB, Tembe V (1975) Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med Soc Exp Biol Med NY N 149(4):926–929CrossRef
54.
Pak CY, Hayashi Y, Arnold LH (1976) Heterogeneous nucleation with urate, calcium phosphate and calcium oxalate. Proc Soc Exp Biol Med Soc Exp Biol Med NY N 153(1):83–87CrossRef
55.
Pak CY, Arnold LH (1975) Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med Soc Exp Biol Med NY N 149(4):930–932CrossRef
56.
Smith MJ (1977) Placebo versus allopurinol for renal calculi
57.
Smith MJ (1973) Allopurinol and calcium-stone formers. Lancet Lond Engl 1(7798):315CrossRef
58.
Coe FL (1977) Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 87(4):404–410PubMedCrossRef
59.
Ettinger B, Tang A, Citron JT, Livermore B, Williams T (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315(22):1386–1389PubMedCrossRef
60.
Hallson PC, Rose GA (1976) Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment. Br J Urol 48(7):515–524PubMedCrossRef
61.
Daudon M, Jungers P, Lacour B (2004) Clinical value of crystalluria study. Ann Biol Clin (Paris) 62(4):379–393
62.
Robertson WG, Peacock M, Nordin BE (1969) Calcium crystalluria in recurrent renal-stone formers. Lancet Lond Engl 2(7610):21–24CrossRef
63.
Robert M, Boularan AM, Delbos O, Guiter J, Descomps B (1998) Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects. Urol Int 60(1):41–46PubMedCrossRef
64.
Fuselier HA, Moore K, Lindberg J et al (1998) Agglomeration inhibition reflected stone-forming activity during long-term potassium citrate therapy in calcium stone formers. Urology 52(6):988–994PubMedCrossRef
65.
Kok DJ, Papapoulos SE, Bijvoet OL (1990) Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 37(1):51–56PubMedCrossRef
66.
Hess B, Jordi S, Zipperle L, Ettinger E, Giovanoli R (2000) Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 15(3):366–374
67.
Evan AP, Lingeman JE, Coe FL et al (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111(5):607–616PubMedPubMedCentralCrossRef
68.
Evan AP, Lingeman JE, Coe FL et al (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67(2):576–591PubMedCrossRef
69.
Evan AP, Coe FL, Lingeman JE et al (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69(12):2227–2235PubMedCrossRef
70.
Evan AP, Lingeman J, Coe F et al (2007) Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 71(8):795–801PubMedCrossRef
71.
Evan AE, Lingeman JE, Coe FL et al (2008) Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int 74(2):223–229PubMedCrossRef
72.
Evan AP, Lingeman JE, Coe FL et al (2009) Intra-tubular deposits, urine and stone composition are divergent in patients with ileostomy. Kidney Int 76(10):1081–1088PubMedPubMedCentralCrossRef
73.
Evan AP, Lingeman JE, Worcester EM et al (2010) Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease. Kidney Int 78(3):310–317PubMedPubMedCentralCrossRef
74.
Evan AP, Worcester EM, Williams JC, et al (2015) Biopsy proven medullary sponge kidney: clinical findings, histopathology, and role of osteogenesis in stone and plaque formation. Anat Rec Hoboken NJ 2007 298(5):865–77
75.
76.
Daudon M, Bader CA, Jungers P (1993) Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc 7(3):1081–1104–1106
77.
Borofsky MS, Paonessa JE, Evan AP et al (2015) Introduction of a renal papillary grading system for patients with nephrolithiasis. J Endourol Part B Videourol 150626110953002
78.
Borofsky MS, Paonessa JE, Evan AP et al (2016) A proposed grading system to standardize the description of renal papillary appearance at the time of endoscopy in patients with nephrolithiasis. J Endourol Endourol Soc 30(1):122–127CrossRef
79.
Strohmaier WL, Hörmann M, Schubert G (2013) Papillary calcifications: a new prognostic factor in idiopathic calcium oxalate urolithiasis. Urolithiasis 41(6):475–479PubMedCrossRef
80.
Krambeck AE, Lieske JC, Li X et al (2013) Current computed tomography techniques can detect duct of Bellini plugging but not Randall’s plaques. Urology 82(2):301–306PubMedPubMedCentralCrossRef
81.
Ciudin A, Luque Galvez MP, Salvador Izquierdo R et al (2013) Validation of Randall’s plaque theory using unenhanced abdominal computed tomography. Urology 81(2):246–249PubMedCrossRef
82.
83.
Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol CJASN 6(8):2069–2075PubMedCrossRef
84.
Ferraro PM, D’Addessi A, Alessandro D, Gambaro G, Giovanni G (2015) Randall’s plaques, plugs and the clinical workup of the renal stone patient. Urolithiasis 43(Suppl 1):59–61PubMed
85.
Kasidas GP, Samuell CT, Weir TB (2004) Renal stone analysis: why and how? Ann Clin Biochem 41(Pt 2):91–97PubMedCrossRef
86.
Krambeck AE, Khan NF, Jackson ME, Lingeman JE, McAteer JA, Williams JC (2010) Inaccurate reporting of mineral composition by commercial stone analysis laboratories: implications for infection and metabolic stones. J Urol 184(4):1543–1549PubMedPubMedCentralCrossRef
87.
Primiano A, Persichilli S, Gambaro G et al (2014) FT-IR analysis of urinary stones: a helpful tool for clinician comparison with the chemical spot test. Dis Markers 2014
88.
Daudon M, Jungers P, Bazin D (2008) Peculiar morphology of stones in primary hyperoxaluria. N Engl J Med 359(1):100–102PubMedCrossRef
89.
Dessombz A, Letavernier E, Haymann J-P, Bazin D, Daudon M (2015) Calcium phosphate stone morphology can reliably predict distal renal tubular acidosis. J Urol 193(5):1564–1569PubMedCrossRef
90.
Talati J, Tiselius H-G, Albala DM, Ye Z (eds) (2012) Urolithiasis: basic science and clinical practice. Springer, London
91.
Hartman R, Kawashima A, Takahashi N et al (2012) Applications of dual-energy CT in urologic imaging: an update. Radiol Clin North Am 50(2):191–205
92.
Williams JC, McAteer JA, Evan AP, Lingeman JE (2010) Micro-computed tomography for analysis of urinary calculi. Urol Res 38(6):477–484PubMedCrossRef
93.
Hesse A, Kruse R, Geilenkeuser W-J, Schmidt M (2005) Quality control in urinary stone analysis: results of 44 ring trials (1980–2001). Clin Chem Lab Med 43(3):298–303PubMedCrossRef
94.
Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G (2003) Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol 169(6):2026–2029PubMedCrossRef
95.
Daudon M, Bouzidi H, Bazin D (2010) Composition and morphology of phosphate stones and their relation with etiology. Urol Res 38(6):459–467PubMedCrossRef
96.
Edvardsson VO, Goldfarb DS, Lieske JC et al (2013) Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol Berl Ger 28(10):1923–1942CrossRef
97.
Strauss AL, Coe FL, Parks JH (1982) Formation of a single calcium stone of renal origin. Clinical and laboratory characteristics of patients. Arch Intern Med 142(3):504–507PubMedCrossRef
98.
Mardis HK, Parks JH, Muller G, Ganzel K, Coe FL (2004) Outcome of metabolic evaluation and medical treatment for calcium nephrolithiasis in a private urological practice. J Urol 171(1):85–88PubMedCrossRef
99.
Rule AD, Lieske JC, Li X, Melton LJ, Krambeck AE, Bergstralh EJ (2014) The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol JASN 25(12):2878–2886PubMedCrossRef
100.
Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A (1996) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. J Urol 155:839–843PubMedCrossRef
101.
Sarica K, Inal Y, Erturhan S, Yağci F (2006) The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 34(3):184–189PubMedCrossRef
102.
Kessler T, Hesse A (2000) Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects. Br J Nutr 84(6):865–871PubMed
103.
Karagülle O, Smorag U, Candir F et al (2007) Clinical study on the effect of mineral waters containing bicarbonate on the risk of urinary stone formation in patients with multiple episodes of CaOx-urolithiasis. World J Urol 25(3):315–323PubMedCrossRef
104.
Siener R, Hesse A (2003) Fluid intake and epidemiology of urolithiasis. Eur J Clin Nutr 57(Suppl 2):S47–S51PubMedCrossRef
105.
Ferraro PM, Taylor EN, Gambaro G, Curhan GC (2013) Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol CJASN 8:1389–1395PubMedCrossRef
106.
Shuster J, Jenkins A, Logan C et al (1992) Soft drink consumption and urinary stone recurrence: a randomized prevention trial. J Clin Epidemiol 45:911–916PubMedCrossRef
107.
Taylor EN, Fung TT, Curhan GC (2009) DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol JASN 20:2253–2259PubMedCrossRef
108.
Soldati L, Bertoli S, Terranegra A et al (2014) Relevance of Mediterranean diet and glucose metabolism for nephrolithiasis in obese subjects. J Transl Med 12(1):34PubMedPubMedCentralCrossRef
109.
Turney BW, Appleby PN, Reynard JM, Noble JG, Key TJ, Allen NE (2014) Diet and risk of kidney stones in the Oxford cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Epidemiol 29(5):363–369PubMedCrossRef
110.
Kocvara R, Plasgura P, Petrík A, Louzenský G, Bartonícková K, Dvorácek J (1999) A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 84(4):393–398
111.
Taylor EN, Stampfer MJ, Curhan GC (2004) Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol JASN 15(12):3225–3232PubMedCrossRef
112.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328(12):833–838PubMedCrossRef
113.
Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ (1997) Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126(7):497–504PubMedCrossRef
114.
Curhan GC, Willett WC, Knight EL, Stampfer MJ (2004) Dietary factors and the risk of incident kidney stones in younger women: Nurses’ Health Study II. Arch Intern Med 164(8):885–891PubMedCrossRef
115.
Sorensen MD, Kahn AJ, Reiner AP et al (2012) Impact of nutritional factors on incident kidney stone formation: a report from the WHI OS. J Urol 187(5):1645–1649PubMedPubMedCentralCrossRef
116.
117.
Bleich HL, Moore MJ, Lemann J, Adams ND, Gray RW (1979) Urinary calcium excretion in human beings. N Engl J Med 301(10):535–541PubMedCrossRef
118.
Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB (2000) Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 13(3):169–177PubMed
119.
Nouvenne A, Meschi T, Prati B et al (2010) Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am J Clin Nutr 91(3):565–570PubMedCrossRef
120.
Taylor EN, Curhan GC (2007) Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol JASN 18(7):2198–2204PubMedCrossRef
121.
Taylor EN, Curhan GC (2008) Determinants of 24-hour urinary oxalate excretion. Clin J Am Soc Nephrol CJASN 3(5):1453–1460PubMedCrossRef
122.
Meschi T, Maggiore U, Fiaccadori E et al (2004) The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 66:2402–2410PubMedCrossRef
123.
La Vecchia C, Decarli A, Pagano R (1998) Vegetable consumption and risk of chronic disease. Epidemiol Camb Mass 9(2):208–210CrossRef
124.
Trinchieri A, Lizzano R, Marchesotti F, Zanetti G (2006) Effect of potential renal acid load of foods on urinary citrate excretion in calcium renal stone formers. Urol Res 34(1):1–7PubMedCrossRef
125.
Ferraro PM, Mandel EI, Curhan GC, Gambaro G, Taylor EN (2015) Diet-dependent net acid load, protein intake, and risk of incident kidney stones. J Am Soc Nephrol JASN 26(SA-OR077)
126.
Thomas LDK, Elinder C-G, Tiselius H-G, Wolk A, Akesson A (2013) Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med 173(5):386–388PubMedCrossRef
127.
Ferraro PM, Curhan GC, Gambaro G, Taylor EN (2016) Total, dietary, and supplemental vitamin c intake and risk of incident kidney stones. Am J Kidney Dis Off J Natl Kidney Found 67(3):400–407CrossRef
128.
Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354(7):669–683PubMedCrossRef
129.
Pak CY, Sakhaee K, Fuller CJ (1983) Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy. Trans Assoc Am Physicians 96:294–305PubMed
130.
Pak CY, Sakhaee K, Fuller C (1986) Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30(3):422–428PubMedCrossRef
131.
Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158(6):2069–2073PubMedCrossRef
132.
Sakhaee K, Nicar M, Hill K, Pak CY (1983) Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 24(3):348–352PubMedCrossRef
133.
Fernández-Rodríguez A, Arrabal-Martín M, García-Ruiz MJ, Arrabal-Polo MA, Pichardo-Pichardo S, Zuluaga-Gómez A (2006) The role of thiazides in the prophylaxis of recurrent calcium lithiasis. Actas Urol Esp 30:305–309PubMedCrossRef
134.
Borghi L, Meschi T, Guerra A, Novarini A (1993) Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences
135.
Ala-Opas M, Elomaa I, Porkka L, Alfthan O (1987) Unprocessed bran and intermittent thiazide therapy in prevention of recurrent urinary calcium stones. Scand J Urol Nephrol 21(4):311–314PubMedCrossRef
136.
Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215(4):383–389PubMedCrossRef
137.
Scholz D, Schwille PO, Sigel A (1982) Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 128(5):903–907PubMed
138.
Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139(4):679–684PubMed
139.
Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL (2006) Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48(2):219–224PubMedCrossRef
140.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288(23):2981–2997CrossRef
141.
Breslau NA, Heller HJ, Reza-Albarrán AA, Pak CY (1998) Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: a randomized double-blind trial. J Urol 160(3 Pt 1):664–668PubMed
142.
Heller HJ, Reza-Albarrán AA, Breslau NA, Pak CY (1998) Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. J Urol 159(5):1451–1455–1456
143.
Parks JH, Coe FL, Evan AP, Worcester EM (2009) Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 24(1):130–136
144.
Buchholz NNP, El Howairis MEF, Durner L et al (2015) Acceptance of mixed scientific and clinical activities in a sub-speciality urology meeting. Urolithiasis 43(2):101–105PubMedCrossRef
145.
Bos D, Abara E, Parmar MS (2014) Knowledge, attitudes, and practice patterns among healthcare providers in the prevention of recurrent kidney stones in Northern Ontario. Can Urol Assoc J J Assoc Urol Can 8(11–12):E795–E804CrossRef
Metadata
Title
Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement
Publication date
01-12-2016
Published in
Journal of Nephrology / Issue 6/2016
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-016-0329-y

Other articles of this Issue 6/2016

Journal of Nephrology 6/2016 Go to the issue

Original Article

Dialysis requirement, long-term major adverse cardiovascular events (MACE) and all-cause mortality in hospital acquired acute kidney injury (AKI): a propensity-matched cohort study

Original Article

Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions

Original Article

Geographic disparities in mortality among the end stage renal disease patients: an analysis of the United States Renal Data System, 2007–08

Original Article

Urinary retinol-binding protein as a risk factor of poor prognosis in acute-on-chronic renal injury

Original Article

Podocyturia is significantly elevated in untreated vs treated Fabry adult patients

Review

ADPKD: clinical issues before and after renal transplantation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits